Nervous System Diseases

Symptoms and General Pathology

All Conditions

Neuralgia

Pain

Peripheral Nervous System Diseases

Neuromuscular Diseases

Neurologic Manifestations

Dermatologic Agents

All Drugs and Chemicals

Capsaicin

Cancer patients presenting neuropathic pain secondary to their anti cancer treatments will receive patch of capsaicin (qutenza) on the painful zones..

Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.

Qutenza

Stéphanie Morisson, MD

In the oncology area, neuropathic pains are relatively frequent and can be induced by surgery, radiotherapy, or chemotherapy. In usual practice, some units are using qutenza in order to reduce neuropathic pain even though using of this patch for a population of cancer patients has never been demonstrated so far in a prospective study. The present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients.

Drugs for neuropathic pains are generally represented by antidepressants, anti-epileptics, opioids, lidocaine patch. However, these drugs can frequently be insufficient, and/or can lead to side effects. Qutenza (8% capsaicin patch) presents an interesting alternative.

Qutenza efficacy has been shown in five principal studies conducted on 1988 adults affected by moderate or severe neuropathic pains. All patients presented Postherpetic neuralgia, or HIV associated therapy, or painful diabetic peripheric neuropathies. These studies led to qutenza approbation in Europe and in States in 2009.

In oncology, neuropathic pains are relatively frequent and can be induced by the three big actors of the anti-cancerous therapeutic arsenal (surgery, radiotherapy, chemotherapy). In usual practice, some units are usually using qutenza, but the use of this patch for this kind of patients has not been shown in a prospective study. Advantages of this treatment are numerous, and results presented in other therapeutic area are encouraging its use in oncology.

The present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients.

Cancer patients treated with qutenza (capsaicin patch)

Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain

Percentage of responders to capsaicin at one month after the first patch application will be calculated with a relief scale completed by patients.

Maximum value of relief will be calculated for patients with relief scale completed by patients at three months after the patch application.

Correlation coefficient between maximal value of relief and time between the beginning of painful signs and first patch application.

Minimal, average, and maximal values of neuropathic pain reported on visual analog scale will be evaluated.

Capsaicin patch induced toxicities will be reported, and quoted according to CTCAE version 4.4.

Number of days of response reported by patients where patch are efficient will be reported

Number of days between the patch set and the apparition of the first effect on patients will be reported.

Number of prescribed antalgics will be reported for each patient.

Percentage of patients with an obligation to report their chemotherapy because of the pain will be calculated.

Percentage of patients who have received at least 75% of the chemotherapy prescribed will be reported.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain	NCT03317613	Neuropathic Pai...	Qutenza	18 Years -	Centre Hospitalier Universitaire de Saint Etienne
Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain	NCT03317613	Neuropathic Pai...	Qutenza	18 Years -	Centre Hospitalier Universitaire de Saint Etienne

Spots Global Cancer Trial Database for qutenza

Every month we try and update this database with for qutenza cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for qutenza

Every month we try and update this database with for qutenza cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for qutenza cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.